Medicine and Dentistry
Adenocarcinoma
26%
Biological Marker
12%
Brachytherapy
10%
Brain Metastasis
70%
Brain Radiation
12%
Brain Tumor
12%
Carmustine
9%
Chemoradiotherapy
35%
Cisplatin
19%
Clear Cell Renal Cell Carcinoma
8%
Clinical Trial
19%
Disease
26%
Drug Megadose
12%
Esophageal Cancer
29%
Esophagectomy
9%
Esophagus
14%
Fluorouracil
9%
Ganglioglioma
28%
Gastroesophageal Junction
14%
Glioblastoma
72%
Immune Checkpoint Inhibitor
11%
Intensity Modulated Radiation Therapy
17%
Lymphocytopenia
10%
Magnetic Resonance Imaging
32%
Malignant Neoplasm
23%
Metastatic Carcinoma
34%
Neoplasm
77%
Neural Stem Cell
9%
Nodular Melanoma
12%
Oncology
25%
Overall Survival
21%
Prognostic Factor
8%
Radiation Necrosis
15%
Radiation Therapy
100%
Radiosurgery
22%
Recurrent Disease
23%
Spine Metastasis
17%
Stereotactic Body Radiation Therapy
31%
Stereotactic Radiosurgery
55%
Stereotactic Radiotherapy
16%
Stomach Cancer
16%
Surgery
28%
Survival Rate
13%
Systemic Therapy
22%
Temozolomide
15%
Tumor Progression
15%
Tumor Recurrence
12%
Tumor Treating Fields
9%
Vestibular Schwannoma
10%
Whole Brain Radiotherapy
11%
Keyphrases
Adenocarcinoma
9%
Brain Metastases
58%
Chemoradiation
11%
Chemotherapy
16%
Cisplatin
9%
Clinical Trials
10%
Concurrent Chemoradiotherapy
9%
Esophageal Cancer
19%
Gastric Cancer
9%
Gastroesophageal Junction Cancer
9%
Glioblastoma
36%
Glioblastoma multiforme
10%
High-grade Glioma
16%
Immune Checkpoint Inhibitors
11%
Karnofsky Performance Status
11%
Local Control
14%
Magnetic Resonance Imaging
16%
Malignant Glioma
9%
Metastatic Disease
9%
MRI-guided
9%
Multi-institutional
10%
Neoadjuvant Chemoradiotherapy (nCRT)
9%
Newly Diagnosed
16%
Newly Diagnosed Glioblastoma
23%
Overall Survival
13%
Pathological Complete Response
11%
Phase II Study
17%
Radiation Dose
9%
Radiation Necrosis
9%
Radiation Therapy
33%
Radionecrosis
12%
Radiosurgery
23%
Radiotherapy
30%
Recurrence Pattern
13%
Resection
8%
Solid Tumors
9%
Spectroscopic MRI
17%
Stereotactic Body Radiation Therapy
9%
Stereotactic Body Radiotherapy
10%
Stereotactic Radiosurgery
48%
Stereotactic Radiotherapy
9%
Survival Outcomes
11%
Systemic Therapy
18%
T1-weighted
9%
Temozolomide
14%
Tumor
31%
Tumor Progression
14%
Tumor Treating Fields
9%
Vestibular Schwannoma
10%
Whole Brain Radiation Therapy
10%